TY - JOUR AU - Stein, Mark N. AU - Malhotra, Jyoti AU - Tarapore, Rohinton S. AU - Malhotra, Usha AU - Silk, Ann W. AU - Chan, Nancy AU - Rodriguez, Lorna AU - Aisner, Joseph AU - Aiken, Robert D. AU - Mayer, Tina AU - Haffty, Bruce G. AU - Newman, Jenna H. AU - Aspromonte, Salvatore M. AU - Bommareddy, Praveen K. AU - Estupinian, Ricardo AU - Chesson, Charles B. AU - Sadimin, Evita T. AU - Li, Shengguo AU - Medina, Daniel J. AU - Saunders, Tracie AU - Frankel, Melissa AU - Kareddula, Aparna AU - Damare, Sherrie AU - Wesolowsky, Elayne AU - Gabel, Christian AU - El-Deiry, Wafik S. AU - Prabhu, Varun V. AU - Allen, Joshua E. AU - Stogniew, Martin AU - Oster, Wolfgang AU - Bertino, Joseph R. AU - Libutti, Steven K. AU - Mehnert, Janice M. AU - Zloza, Andrew PY - 2019 DA - 2019/05/22 TI - Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration JO - Journal for ImmunoTherapy of Cancer SP - 136 VL - 7 IS - 1 AB - ONC201 is a small molecule antagonist of DRD2, a G protein-coupled receptor overexpressed in several malignancies, that has prolonged antitumor efficacy and immunomodulatory properties in preclinical models. The first-in-human trial of ONC201 previously established a recommended phase II dose (RP2D) of 625 mg once every three weeks. Here, we report the results of a phase I study that evaluated the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of weekly ONC201. SN - 2051-1426 UR - https://doi.org/10.1186/s40425-019-0599-8 DO - 10.1186/s40425-019-0599-8 ID - Stein2019 ER -